SparingVision
Oct 22, 2020
GSK’s RSV vaccine; SparingVision’s interest in gene therapy; InCarda’s raise; BridgeBio’s R&D deal
GSK eyes robust immune response from RSV vaccine Cold viruses mostly do not get much attention in terms of R&D. They usually make humans feel miserable for a few days, and later than clear up. However, some cold viruses can hit vulnerable people much harder, which leads to pneumonia and hospitalizations. Th...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
